CLINICAL RESEARCH: HEART FAILURE
Detection of Soluble Angiotensin-Converting Enzyme 2 in Heart FailureInsights Into the Endogenous Counter-Regulatory Pathway of the Renin-Angiotensin-Aldosterone System
Slava Epelman, MD, PhD*,
W.H. Wilson Tang, MD, FACC , ,
Stephen Y. Chen, MD*,
Frederick Van Lente, PhD ,
Gary S. Francis, MD, FACC and
Subha Sen, PhD, DSc ,*
* Department of Internal Medicine, Heart and Vascular Institute, Cleveland, Ohio
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland, Ohio
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Manuscript received December 3, 2007;
revised manuscript received February 7, 2008,
accepted February 26, 2008.
* Reprint requests and correspondence: Dr. Subha Sen, Department of Molecular Cardiology, NB50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195. (Email: sens{at}ccf.org).
Objectives: We sought to determine whether circulating soluble angiotensin-converting enzyme 2 (sACE2) is increased in the plasma of patients with heart failure (HF).
Background: Angiotensin-converting enzyme 2 (ACE2) is an integral membrane protein that antagonizes the actions of angiotensin II and prevents the development of HF in animal models. However, because of the need for invasive cardiac tissue sampling, little is known about whether ACE2 is involved in the pathophysiology of HF in humans.
Methods: We developed a sensitive and specific assay to measure sACE2 activity in human plasma and screened a heterogeneous group of patients suspected of having clinical HF.
Results: Increasing sACE2 plasma activity strongly correlated with a clinical diagnosis of HF (p = 0.0002), worsening left ventricular ejection fraction (p < 0.0001), and increasing B-type natriuretic peptide levels (p < 0.0001). Similar to B-type natriuretic peptide, sACE2 activity reflected the severity of HF, with increasing levels associated with worsening New York Heart Association functional class (p < 0.0001). These associations were independent of other disease states and medication use. We found that sACE2 activity was increased in patients with both ischemic and nonischemic cardiomyopathies and also in patients with clinical HF but a preserved left ventricular ejection fraction.
Conclusions: Soluble ACE2 activity is increased in patients with HF and correlates with disease severity, suggesting that a cardioprotective arm of the renin-angiotensin-aldosterone system is active in HF.
Key Words: heart failure ACE2 hypertrophy soluble
|
Abbreviations and Acronyms
| | ACE2 = angiotensin-converting enzyme 2 | | Ang = angiotensin | | BNP = B-type natriuretic peptide | | HF = heart failure | | NYHA = New York Heart Association | | RAAS = renin-angiotensin-aldosterone system | | sACE2 = soluble angiotensin-converting enzyme 2 |
|
Related Articles
-
An ACE in the Hole: Alternative Pathways of the Renin Angiotensin System and Their Potential Role in Cardiac Remodeling
- Barry Greenberg
J. Am. Coll. Cardiol. 2008 52: 755-757.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A27-A28.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G. Boerrigter, L. C. Costello-Boerrigter, G. J. Harty, B. K. Huntley, A. Cataliotti, H. Lapp, and J. C. Burnett Jr.
B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity
Am J Physiol Regulatory Integrative Comp Physiol,
June 1, 2009;
296(6):
R1744 - R1750.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Greenberg
An ACE in the Hole: Alternative Pathways of the Renin Angiotensin System and Their Potential Role in Cardiac Remodeling
J. Am. Coll. Cardiol.,
August 26, 2008;
52(9):
755 - 757.
[Full Text]
[PDF]
|
 |
|
|